AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00052377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03572335 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PFT's (pulmonary function testing)
Description: The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.
Study NCT04050254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
Study NCT04050254 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
Study NCT04050254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
Study NCT04050254 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
Study NCT01083264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
Study NCT01083264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
Study NCT01083264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
Study NCT00611364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy and education meetings
Description: Physical therapy was realized three two times per week and education meeting every fifteen days
Study NCT00611364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education meetings
Description: This group only participed of education meeting (every fifteen days)
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM
Study NCT03707717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT and orally
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or SC
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally
Study NCT00771875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
Study NCT02989363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device O-Arm in DBS
Description: Deep brain stimulation surgeries with device O-Arm
Study NCT02989363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device O-Arm in RAQUIS
Description: Complex back surgeries with the device O-Arm
Study NCT04402489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04402489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117 Low Dose
Description: MT-7117 Low Dose
Study NCT04402489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117 High Dose
Description: MT-7117 High Dose
Study NCT01491958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first.
Study NCT01491958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
Study NCT02665715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate meals
Description: Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
Study NCT02665715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard carbohydrate meals
Description: Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
Study NCT00599079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
Study NCT05256147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Patient will receive ibuprofen 400 mg before the phototherapy session.
Study NCT00573443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg
Description: Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Study NCT00573443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
Description: Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Study NCT00573443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Study NCT04599998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire
Description: Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
Study NCT04266340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 2.5µg/kg intranasal dexmedetomidine group
Study NCT04266340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 0.5mg/kg oral midazolam
Study NCT04266340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 0.05mg/kg intravenous injection midazolam
Study NCT04266340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: no premedication
Study NCT00274651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Study NCT02082808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
Study NCT02082808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV
Description: DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
Study NCT02908776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
Study NCT02908776 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
Study NCT05181969 — intervention group
Intervention type: DEVICE
Intervention: Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)
Description: Lipoprotein apheresis Method I
Study NCT05181969 — intervention group
Intervention type: DEVICE
Intervention: Lipid filtration (Octo Nova®, Diamed Medizintechnik)
Description: Lipoprotein apheresis Method II
Study NCT05181969 — intervention group
Intervention type: DEVICE
Intervention: Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)
Description: Lipoprotein apheresis Method III
Study NCT05181969 — intervention group
Intervention type: DEVICE
Intervention: Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)
Description: Lipoprotein apheresis Method IV
Study NCT01665690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient delivered partner therapy
Description: The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.
Study NCT01665690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted public health partner services
Description: During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
Study NCT02989363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Not device O-Arm in DBS
Description: Deep brain stimulation surgeries without the device O-Arm
Study NCT02989363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Not device O-Arm in RAQUIS
Description: Complex back surgeries without the device O-Arm
Study NCT04574154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIB
Description: FIB with ultrasound: Ropivacaine 0.5% 40 ml
Study NCT04574154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB
Description: ESPB (L4) with ultrasound: Ropivacaine 0.5% 40 ml
Study NCT04574154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: bupivacaine 0,5% 2.2 ml
Study NCT02617563 — intervention group
Intervention type: DEVICE
Intervention: Minimally invasive lumbar fusion
Description: Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
Study NCT01187290 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy
Description: Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
Study NCT01187290 — intervention group
Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: neoadjuvant chemoradiotherapy
Description: Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
Study NCT01491958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Day +1, +3, and +6 and +11
Study NCT03279978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet
Study NCT03279978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01367743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine perfusion
Description: perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
Study NCT01367743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine perfusion
Description: perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
Study NCT04553887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: single agent, 110mg p.o once daily until disease progressed
Study NCT01979510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0663B
Description: MK-0663B once daily for 8 days.
Study NCT01979510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOLOCAM PLUS®
Description: DOLOCAM PLUS® once daily for 8 days.
Study NCT01979510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500 mg
Description: Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
Study NCT03401606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished
Study NCT03401606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
Study NCT01581411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator
Description: Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
Study NCT02045199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tested product : V0111 cream
Description: Application twice a day during 28 days
Study NCT02045199 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application twice a day during 28 days
Study NCT04237883 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard communication email
Description: This is the base communication that all physicians will receive.
Study NCT04237883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard communication email
Description: This is the base communication that all physicians will receive.
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT04237883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social comparison Intervention
Description: The social comparison is added onto the standard communication email to provide some peer comparison between the physicians.
Study NCT04237883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership Training
Description: Clinic and Physician leads will be provided with a clinic leadership training seminars in leadership, quality improvement, and support from the Quality Improvement team at UCLA Health.
Study NCT01980446 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Auditory-evoked potentials
Description: cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
Study NCT02012816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peer-referral incentive program to increase VMMC uptake
Description: The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally
Study NCT00656214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene
Description: 08 mg/day in two divided dosage
Study NCT00656214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two divided dosage
Study NCT04416516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
Study NCT00016302 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo cranial irradiation
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelarabine
Description: Given IV
Study NCT02813538 — intervention group
Intervention type: DRUG
Intervention: Indocyanine green clearance
Description: To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
Study NCT02813538 — intervention group
Intervention type: OTHER
Intervention: Thromboelastometry
Description: To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
Study NCT02589587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
Study NCT02589587 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: lean control group
Study NCT04707248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6000a
Description: Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
Study NCT04707248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6000a
Description: Intravenous administration at RDE on Day 1 of Cycle 1
Study NCT05978869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical fitness training
Description: Through a three-step process, gamified physical fitness training was developed by a multidisciplinary team.
Study NCT01344122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KPI training only
Description: See comparison arm description.
Study NCT01344122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KPI plus OLI
Description: See experimental arm description.
Study NCT03719573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric intervention
Description: A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
Study NCT02243176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: The dose of saxaglitpin will be 5mg oral qd.